Lyfegen is a global healthtech SaaS analytics company providing a value-based agreement platform for drugs, therapies and devices. Health insurances, pharma, medtech companies & hospitals use the secure platform for thousands of payment models throughout Switzerland, Europe, the Middle East and North America.
Lyfegen was founded by individuals with decades of experience in healthcare, pharma and technology, pioneering the shift away from volume-based and fee-for-service healthcare to value-based healthcare.
The Lyfegen Platform supports the negotiation and automated execution of value-based payment models cost-effectively and at scale using real-world data and machine learning. Globally renowned health insurances, hospitals, pharma & medtech companies have already implemented Lyfegen's patent-pending platform to scale value-based payment models for drugs, therapies and devices, improving access to treatments and patient outcomes.
Questions to Girisha Fernando, CEO of Lyfegen:
What inspiration or idea is your company built on?
Baby Lea Story. Lea and many other babies in the world have a deadly disease for which there is a cure but the healthcare systems are failing them and not able to pay for those therapies, forcing parents to raise more than CHF 2 Million through crowdfunding to pay for the therapy.
Lyfegen’s vision is to help patients to receive the healthcare treatments they need by making drugs more affordable.
What are your main export markets and why?
Ultra high drug prices and patients not receiving the healthcare treatments they need is a global challenge. Lyfegen is focused on starting to help patients in Europe, the Middle East and North America.
Connecting us with decision makers within healthcare systems, from governments, health inurances and pharma. With the combination of being an Innosuisse registed startup, working together with S-GE gives us credibility and trust.
What positive or negative surprises have you encountered in export? What are your biggest challenges at the moment?
The misalignment of incentives in healthcare is a big challenge. Even if certain change makes sense and helps patients, healthcare is very much seen as a business case and costs rather than an investment and focus on health equity.
Due to the highly complex market, the US is a challenge to enter. Many different stakeholders that follow different interests and do not necessarily want to work with each other for the benefit patients.
What are you particularly proud of?
We have already helped thousands of patients to receive their healthcare treatments. After just four years of existence, Lyfegen is working with the largest healthcare entities such as Governments, Health Insurances, Hospitals and 8 out of the top 10 largest Pharma companies.
To what extent did S-GE support you in your success?
Connecting us with decision makers within healthcare systems, from governments, health insurances and Pharma. With the combination of being an Innosuisse registered startup, working together with S-GE gives us credibility and trust.
